Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Article

Upregulation of the Mammalian Target of Rapamycin Complex 1 Pathway by Ras Homolog Enriched in Brain in Pancreatic β-Cells Leads to Increased β-Cell Mass and Prevention of Hyperglycemia

  1. Suirin Hamada1,
  2. Kenta Hara1,
  3. Takeshi Hamada1,
  4. Hisafumi Yasuda1,
  5. Hiroaki Moriyama1,
  6. Rika Nakayama2,
  7. Masao Nagata1 and
  8. Koichi Yokono1
  1. 1Department of Internal and Geriatric Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;
  2. 2Laboratory for Animal Resources and Genetic Engineering, Center for Developmental Biology (CDB), RIKEN, Kobe, Japan.
  1. Corresponding author: Kenta Hara, harak{at}kobe-u.ac.jp.
Diabetes 2009 Jun; 58(6): 1321-1332. https://doi.org/10.2337/db08-0519
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
    • Download figure
    • Open in new tab
    • Download powerpoint
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Activation of the mTORC1 pathway by overexpression of FLAG-Rheb in pancreatic β-cells. Islets isolated from mice of each genotype were incubated either in 50% RPMI medium without FCS (A, B, and D) or in RPMI medium (C), or they were stimulated with 100 nmol/l IGF-1 (B) or 15% FCS (D) as indicated. The same amounts of cellular extracts were analyzed by immunoblotting with the antibodies to Rheb, phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein, phospho-4EBP1 (Thr37/46 or Thr70), phospho-p70 S6 kinase (Thr389), p70 S6 kinase, phospho-PKB (Ser473), PKB, phospho-p44/42 MAP kinase (Thr202/Tyr204), p44/42 MAP kinase, or IRS2. A representative experiment is shown. The bottom panel in A shows the same blot as the top panel, except that it was exposed longer to detect the endogenous Rheb (end-Rheb). E: Relative quantification of phospho-S6 (Ser235/236), phospho-4EBP1 (T37/46 or T70), phospho-PKB (Ser473), phospho-p44/42 MAP kinase (Thr202/Tyr204), and IRS2. The immunoblots were scanned, and the optical density for R3 with IGF1 or FCS stimulation (A, B, and D) or the optical density for R3 (C) was set to 100%. F: Immunoprecipitation with the anti-FLAG antibody was performed using lysates of the hypothalamus, muscle, or liver isolated from mice of each genotype and analyzed by immunoblotting with the same antibody. WT, wild type.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Metabolic effects of overexpression of Rheb in pancreatic β-cells. A: Growth curves of R3 or R20 lines of transgenic mice (●) and their wild-type littermates (○). B: Blood glucose concentrations were measured in R3 and R20 transgenic mice and their wild-type littermates in the fed state at 8 and 50 weeks. C: Plasma insulin concentrations were measured in R3 and R20 transgenic mice and their wild-type littermates in the fed state at 8 weeks. D and E: Oral glucose tolerance tests were performed in R3 or R20 transgenic mice (●) and their wild-type littermates (○) at 8 weeks. Glucose concentrations (D) and plasma insulin concentrations (E) are shown. F: Oral glucose tolerance tests were performed in R20 transgenic mice (●) and wild-type littermates (○) at 40 weeks. G: Intraperitoneal insulin tolerance tests were performed in R20 transgenic mice (●) and wild-type littermates (○). H: Intraperitoneal glucose tolerance tests were performed in R20 transgenic mice (●) and wild-type littermates (○). Glucose concentrations and plasma insulin concentrations are shown. Data are the means ± SE of values from six (A), six to eight (B), eight (C), five (D and E), six (F), nine (G), and six (H) animals from each genotype. *P < 0.05; **P < 0.01. WT, wild type.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Increased β-cell mass and cell growth in transgenic mice. A: Hematoxylin and eosin staining of representative pancreatic sections from 8-week-old R3 transgenic mice and their wild-type littermates. B and C: Immunostaining with the anti-FLAG antibody (B) and anti–phospho-S6 (Ser235/236) antibody (C, upper panels) of representative pancreatic sections from 8-week-old R3 transgenic mice and wild-type littermates. Ratio of the number of dark staining cells to the total number of nuclei in islets from transgenic mice and wild-type littermates is shown (C, lower panels). D: Hematoxylin and eosin (H-E) staining and immunostaining with the anti-FLAG antibody of representative pancreatic sections from 90-week-old R3 transgenic mice and their wild-type littermates. E: Immunostaining with the anti-insulin (red) and the anti-glucagon (green) antibodies of representative pancreatic sections from 8-week-old R3 transgenic mice and their wild-type littermates. F: Quantification of β- and α-cell area as a percentage of total pancreatic area in transgenic mice and their wild-type littermates. G: β-Cell mass was calculated by the β-cell area and pancreas weight. H: The relative size of β-cells in the transgenic mice and their wild-type littermates was calculated. I: Immunostaining with anti–Ki-67 antibody of representative pancreatic sections from 9-week-old R3 transgenic mice and their wild-type littermates. Data are the means ± SE of values from four (C), five (F), four (G), and five (H) animals from each genotype. * P < 0.05; ** P < 0.01. WT, wild type. (A high-quality digital representation of this figure is available in the online issue.).

    • Download figure
    • Open in new tab
    • Download powerpoint
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Transgenic mice were resistant to streptozotocin-induced hyperglycemia. A: Doses of 40 mg/kg or 50 mg/kg streptozotocin were administered to R3 line transgenic mice (●) or wild-type littermates (○) for 5 consecutive days (arrows in the figure). Blood glucose concentrations in the fed state were monitored. Data are the means ± SE of values from four (40 mg/kg) or five (50 mg/kg) animals from each genotype. B: A dose of 50 mg/kg streptozotocin was administered to R20 transgenic mice (●) or wild-type littermates (○), and blood glucose concentrations were monitored with mice in the fed state. Data are the means ± SE of values from four animals from each genotype. C and D: Plasma insulin concentration (C) and glucose-to-insulin ratio (D) after administration with or without 50 mg/kg streptozotocin as shown in A. E: Oral glucose tolerance tests were performed in R20 transgenic mice (●) and wild-type littermates (○) 4 weeks after streptozotocin administration as shown in B. Glucose and insulin concentrations are shown. F: Immunostaining with the anti-insulin (red) and anti-glucagon (green) antibodies of representative pancreatic sections from R3 transgenic mice (R3) and their wild-type littermates (WT) 4 weeks after 50 mg/kg streptozotocin administration as shown in A. G: Quantification of β-cell area as a percentage of total pancreatic area in transgenic mice and their wild-type littermates 4 weeks after administration with or without 50 mg/kg streptozotocin as shown in A. H: Immunostaining with anti-insulin (red) antibody and TUNEL assay (green) of representative pancreatic sections from the transgenic mice and their wild-type littermates 1 week after 50 mg/kg streptozotocin administration. Values represent the means ± SE. * P < 0.05; ** P < 0.01. (A high-quality digital representation of this figure is available in the online issue.).

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    A: Transgenic mice were resistant to obesity-induced hyperglycemia. Oral glucose tolerance tests were performed in Ay/Rheb mice (●) and Aylittermates (○). Blood glucose concentrations and plasma insulin concentrations are shown. B: Elimination of the effect of Rheb expression in β-cells after administration with rapamycin. Oral glucose tolerance tests were performed in rapamycin-treated transgenic mice (●) and their rapamycin-treated wild-type littermates (○). Blood glucose and plasma insulin concentrations are shown. Data are the means ± SE of values from five (A and B) animals from each genotype. C: Islets were prepared from rapamycin- or vehicle-treated mice of each genotype and incubated for 1 h in RPMI, and the same amounts of cellular extracts were analyzed by immunoblotting with the antibodies to phospho-S6 ribosomal protein (Ser235/236), phospho-4EBP1 (Thr37/46), or S6 ribosomal protein. * P < 0.05; ** P < 0.01. WT, wild type.

Tables

  • Figures
  • TABLE 1

    Metabolic characteristics of the transgenic mice and their wild-type littermates

    Plasma free fatty acids (mg/dl)Plasma triglycerides (mg/dl)Plasma leptin (ng/ml)
    Wild type1.46 ± 0.13154.6 ± 9.42.09 ± 0.30
    Transgenic1.44 ± 0.77166.8 ± 16.61.57 ± 0.21
    • Data are means ± SE of values from 7–10 animals from each genotype at 8 weeks for plasma triglycerides and leptin or at 10 weeks for plasma free fatty acids.

  • TABLE 2

    Numbers of total and Ki-67–positive nuclei in islets

    Counted islets per animalCounted nuclei per animalNuclei per isletProportion of Ki-67–positive nuclei per islet (%)
    Wild type686,297 ± 664.593 ± 7.61.10 ± 0.08
    Transgenic605,291 ± 567.789 ± 9.71.16 ± 0.13
    • Data are means ± SE of values from four animals from each genotype. Pancreatic sections were immunostained with the anti–Ki-67 antibody followed by counterstaining with hematoxylin as shown inFig. 3I. Numbers of all nuclei and of Ki-67–positive nuclei in the islets of wild-type and transgenic mice were counted.

  • TABLE 3

    Numbers of insulin- and TUNEL-positive nuclei in islets

    Counted islets per animalCounted nuclei per animalNuclei per isletProportion of TUNEL-positive nuclei per islet (%)
    Wild type692,882 ± 567.843 ± 4.30.55 ± 0.15
    Transgenic653,233 ± 495.546 ± 4.00.42 ± 0.11
    • Data are means ± SE of values from five animals from each genotype. Pancreatic sections were double-stained with the anti-insulin antibody and TUNEL assay 1 week after 50 mg/kg streptozotocin administration as shown inFig. 4H. Numbers of all nuclei and of TUNEL-positive nuclei in the insulin-positive cells of wild-type and transgenic mice were counted.

PreviousNext
Back to top

In this Issue

June 2009, 58(6)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Upregulation of the Mammalian Target of Rapamycin Complex 1 Pathway by Ras Homolog Enriched in Brain in Pancreatic β-Cells Leads to Increased β-Cell Mass and Prevention of Hyperglycemia
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Upregulation of the Mammalian Target of Rapamycin Complex 1 Pathway by Ras Homolog Enriched in Brain in Pancreatic β-Cells Leads to Increased β-Cell Mass and Prevention of Hyperglycemia
Suirin Hamada, Kenta Hara, Takeshi Hamada, Hisafumi Yasuda, Hiroaki Moriyama, Rika Nakayama, Masao Nagata, Koichi Yokono
Diabetes Jun 2009, 58 (6) 1321-1332; DOI: 10.2337/db08-0519

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Upregulation of the Mammalian Target of Rapamycin Complex 1 Pathway by Ras Homolog Enriched in Brain in Pancreatic β-Cells Leads to Increased β-Cell Mass and Prevention of Hyperglycemia
Suirin Hamada, Kenta Hara, Takeshi Hamada, Hisafumi Yasuda, Hiroaki Moriyama, Rika Nakayama, Masao Nagata, Koichi Yokono
Diabetes Jun 2009, 58 (6) 1321-1332; DOI: 10.2337/db08-0519
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Article

  • An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
  • Loss of Prohibitin Induces Mitochondrial Damages Altering β-Cell Function and Survival and Is Responsible for Gradual Diabetes Development
  • Cbl-b Is a Critical Regulator of Macrophage Activation Associated With Obesity-Induced Insulin Resistance in Mice
Show more Original Article

Islet Studies

  • Retinol-Binding Protein 4 Activates STRA6, Provoking Pancreatic β-Cell Dysfunction in Type 2 Diabetes
  • Loss of Furin in β-Cells Induces an mTORC1-ATF4 Anabolic Pathway That Leads to β-Cell Dysfunction
  • SKAP2, a Candidate Gene for Type 1 Diabetes, Regulates β-Cell Apoptosis and Glycemic Control in Newly Diagnosed Patients
Show more Islet Studies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.